Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.33 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.30 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210941 | 0.92 | FOLH1 (0.36) | ADORA3ADORA2AFOLH1ADORA1EPHX2 | |
| SCHEMBL13210959 | 0.91 | ADORA3 (0.36) | ADORA3ADORA2AENTPD2ADORA1 | |
| SCHEMBL13211031 | 0.91 | ADORA3 (0.34) | ADORA3ADORA2AFOLH1ENTPD2ADORA1 | |
| SCHEMBL13210939 | 0.84 | ADORA3 (0.40) | ADORA3ADORA2AENTPD2ADORA1EPHX2 | |
| SCHEMBL13211010 | 0.83 | FOLH1 (0.38) | ADORA3ADORA2AFOLH1ADORA1EPHX2 | |
| SCHEMBL13210961 | 0.82 | ADORA3 (0.39) | ADORA3ADORA2AENTPD2ADORA1EPHX2 | |
| SCHEMBL13211025 | 0.81 | ADORA3 (0.37) | ADORA3ADORA2AENTPD2ADORA1 | |
| SCHEMBL14384561 | 0.75 | ADORA3 (0.41) | ADORA3ADORA2AENTPD2ADORA1EPHX2 | |
| SCHEMBL14384567 | 0.75 | ADORA3 (0.41) | ADORA3ADORA2AENTPD2ADORA1EPHX2 | |
| SCHEMBL14387176 | 0.73 | ADORA3 (0.40) | ADORA3ADORA2AENTPD2ADORA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ADORA3 28/4885ADORA2A 32/4885FOLH1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.